NCT07680660Toborzás még nem indult

Efficacy of Lymphatic-Venous Anastomosis Plus Donepezil Versus Donepezil Alone for Alzheimer's Disease

A Multicenter Randomized Controlled Trial on the Efficacy and Safety of Cervical Lymph Vessel/Node-venous Anastomosis Combined With Donepezil Versus Donepezil Alone in the Treatment of Alzheimer's Disease

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. júl. 22.

Rövid összefoglaló (regiszter, angolul)

This study employed a multicenter, randomized controlled trial (RCT) design to evaluate the efficacy and safety of deep cervical lymphatic/lymph node-venous anastomosis combined with oral donepezil compared to donepezil monotherapy in patients with Alzheimer's disease and moderate dementia. Participants were randomized using a central randomization system with stratified block design, with the study center and age group (50-64 years, 65-80 years) as stratification factors. While study participants and surgical investigators could not be blinded due to the nature of the intervention, efficacy assessors and imaging specialists remained blinded to ensure the objectivity and reliability of the findings. The intervention group received deep cervical lymphatic/lymph node-venous anastomosis (detailed surgical procedure is specified in the protocol) in combination with oral donepezil (5-10 mg/day), while the control group received oral donepezil alone. The total treatment and follow-up period was 18 months, with assessments conducted at baseline, 1 week, 1, 3, 6, 12, and 18 months post-operation. These included neuropsychological evaluations (MMSE, MoCA, CDR, BADL, IADL, NPI, AES), neuroimaging (MRI, PET, ultrasound), fluid biomarker analyses (CSF and blood levels of Aβ, Tau, neuroinflammatory factors, etc.), and safety monitoring. The primary efficacy endpoint was the change in CDR-SB score at 12 months post-treatment. Secondary endpoints included changes in multiple cognitive scales, neuroimaging metrics, and biomarkers at 18 months. Safety indicators encompassed adverse event recording, vital signs, and laboratory tests.

Állapot (regiszter): Toborzás még nem indult
Vizsgálattípus: Beavatkozással járó
Résztvevők száma: 216 (tervezett)
Első benyújtás: 2026. jún. 7.
Kezdés: 2026. júl. 15.
Elsődleges befejezés: 2028. szept. 30.
Fő szponzor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Betegségek: Alzheimer-kór
NCT-szám: NCT07680660

Mit vállalsz

Vizsgálat típusa: Beavatkozással járó
Tervezett résztvevők: 216
2026. júl. 15. és az elsődleges befejezés (2028. szept. 30.) között
1 helyszín, 1 országban
Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

Drug addiction (including alcohol, narcotics, and alcohol dependence);
Anti-Aβ monoclonal antibody treatment has been received within half a year;
Previous neck surgery.

Más betegség

Severe heart disease or unstable hemodynamic status;
Severe lung disease, including severe obstructive, restrictive, or mixed ventilatory dysfunction, or acute inflammation within 3 months;
MRI indicates active or acute intracranial lesions, including intracranial infection, space-occupying lesions, major hemorrhage, and ≥4 lobar microbleeds, etc.;
History of cerebral hemorrhage or cerebral infarction with severe residual neurological dysfunction;
Blood diseases, bleeding/coagulation disorders, coagulation dysfunction;
Severe hypertension not effectively controlled, systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg;
The disease requires systemic use of steroids;
Severe infectious diseases, including HIV positivity, severe infection, etc.;
Severe psychiatric disease or potential suicide risk;
Within 3 years after radical surgery for malignant tumor;

Laborértékek

Hepatic insufficiency, AST or ALT \>3 times the upper limit of normal;
Renal insufficiency, GFR \<60 mL/min or need for blood purification treatment;

Egyéb

Presence of contraindications to MRI, ICG angiography, or PET scan;
Presence of contraindications to lumbar puncture;
Abnormal thyroid function;
Moderate or severe stenosis of intracranial or cervical vessels with severe residual neurological dysfunction;
Participation in other interventional clinical trials within the past three months;
In the physician's judgment, poor compliance, inability to complete, or unwillingness to cooperate with regular postoperative follow-up;
Other circumstances that the physician considers unsuitable for this clinical trial;

Kiket keres a vizsgálat

The patient or guardian signs the informed consent form;
Age 50-80 years (≥50 years, ≤80 years), male or female;
The first diagnosis is Alzheimer's disease with dementia;
MMSE score ≤24;
Positive β-amyloid protein PET imaging findings;
HAMD score ≤17;
Hachinski score ≤7;
No AD-related drug treatment has been received within the past 1 month;
ASA grade 1-3 (≥ grade 1, ≤ grade 3);
CDR-SB score of 9.5-15.5.

Életkor a regiszterben: 50 év – 80 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

Helyszín	Város	Ország	Helyszín állapota
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát	Shanghai	Kína	Ismeretlen állapot

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.